An HIV-prevention drug is widely available. Yet at-risk women are getting left behind.

In the U.S., women account for a fifth of new infections. But a persistent lack of education means few even know about the highly effective medication known as PrEP.

Related Keywords

Georgia ,United States ,Texas ,Massachusetts ,Atlanta ,White House ,District Of Columbia ,Minnesota ,South Africa ,California ,Uganda ,San Francisco ,Connecticut ,Americans ,Masonia Traylorspeaks ,Jennifer Kates ,Judithd Auerbach ,Jewel Mullen ,Robert Goldstein ,Krista Martel ,Joe Biden ,Moupali Das ,Haroldj Phillips ,Rochelle Walensky ,Dazon Dixon Diallo ,Mitchell Warren ,White House Office Of National ,University Of California ,Glaxosmithkline ,Us Centers For Disease ,Drug Administration ,Melinda Gates Foundation ,Kaiser Family Foundation ,University Of Texas At Austin ,National Geographic ,Prevention Clinical Development Lead At Gilead Sciences ,International Partnership For Microbicides ,Dell Medical School ,Affordable Care ,Disease Control ,Massachusetts General Hospital ,New England ,Gender Parity ,Clinical Trials ,Clinical Development Lead ,Gilead Sciences ,Well Project ,Viiv Healthcare ,International Partnership ,President Joe Biden ,White House Office ,Affordable Care Act ,Melinda Gates ,Brit Williams ,Economic Hardship Reporting ,